Food Safety and Standards Authority of India (FSSAI) is mandated to lay down science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption. The implementation and enforcement of the Food Safety and Standards (FSS) Act, 2006 is a shared responsibility between the Central and State Governments.

FSSAI has undertaken awareness measure called 'Aaj se Thoda Kam' to address the adverse effects of consuming foods high in fat, salt, and sugar. It encourages consumers to gradually reduce their intake of fat, salt, and sugar through dietary modifications.

FSSAI has also undertaken awareness campaign "Har Label Kuch Kehta Hai" under the ‘Eat Right India’ movement on social media to promote food safety consciousness and healthy eating habits across India. This awareness campaign focuses on empowering consumers to make informed dietary choices by enhancing their understanding of food labels. Food labels contain crucial information about a product's nutritional value, ingredients, and potential allergens.

FSSAI has notified the Food Safety and Standards (Labelling and Display) Regulations, 2020, which lay down comprehensive provisions relating to the labelling of pre-packaged foods. Further, FSSAI has also notified the Food Safety and Standards (Safe Food and Balanced Diets for Children in School) Regulations, 2020 outlining the responsibilities of school authorities to ensure the availability of safe and nutritious food on school premises while also promoting balanced diets in and around school campuses.

FSSAI is fully committed to ensure the availability of safe food products to the consumers across the country. Towards this, regular surveillance, monitoring, inspection and random sampling of various food products are conducted throughout the year by the officials of Food Safety Departments of the respective States/ UTs to check compliance with the quality and safety parameters and other requirements as laid down under FSS Act, 2006, rules & regulations made there under.

The Union Minister of State for Health and Family Welfare, Shri. Prataprao Jadhav stated this in a written reply in the Lok Sabha today.

The Government of India has taken number of steps to reduce dependence on imported active pharmaceutical ingredients (APIs) and promote domestic production. These include the following:

  1. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as PLI scheme for Bulk Drugs): The scheme is aimed at avoiding disruption in supply of critical APIs used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source. The scheme has a budgetary outlay of ₹6,940 crore. Till December 2025, investment of ₹4,814 crore has already been made against an investment commitment of ₹4,329.95 crore over the period of six years in greenfield projects. Further, production capacities have been created for 26 KSMs/DIs/APIs, which were earlier primarily imported. The scheme has resulted in cumulative sales of ₹2,720 crore reported till December 2025, including exports of ₹527.96 crore, thereby avoiding imports worth ₹2,192.04 crore. The tenure of the scheme is till the financial year 2029-30.
  2. PLI Scheme for Pharmaceuticals: The scheme is aimed at enhancing India’s manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. as well as production of APIs/DIs/KSMs other than those notified under the PLI Scheme for Bulk Drugs. It has a budgetary outlay of ₹15,000 crore. As of December 2025, the committed investment of ₹17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with cumulative investment of ₹41,920 crore made in both brownfield and greenfield projects. Further, 726 APIs/KSMs/DIs are being manufactured under the scheme, including 191 which have been manufactured for the first time under the scheme. Cumulative domestic sales of APIs/KSMs/DIs produced under the scheme till December 2025 is worth ₹28,067 crore and thereby contributing to import avoidance. The tenure of the scheme is till the financial year 2028-29.
  3. Scheme for Promotion of Bulk Drug Parks: The scheme has a budgetary outlay of ₹3,000 crore, under which three bulk drug parks have been approved and are at various stages of development in the States of Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective State implementing agencies. The total project cost of these parks is over ₹6,306.68 crore, with Central assistance to the tune of ₹1,000 crore each for creation of common infrastructure facilities. These parks envisage land and utilities such as power, water, effluent treatment plant, steam, solid waste management and warehouse facilities at a subsidised rate to bulk drug or API manufacturers for units set up in the park. The State implementing agencies of the States concerned have also offered fiscal incentives in the form of capital subsidy on fixed capital investment, interest subsidy, State Goods and Services Tax reimbursement, exemption of stamp duty and registration charges, etc. Further, the scheme provides for applicants for allotment of land in the parks to set up units for manufacturing products prioritised in the PLI Scheme for Bulk Drugs to have priority in land allotment.

 As per the information provided by the Department of Fertilizers, the following steps are taken by the Government every season for ensuring timely and adequate supply of fertilizers across the country, including the remote areas:

  1. Before the commencement of each cropping season, the Department of Agriculture and Farmers Welfare (DA&FW), in consultation with all the State Governments, assesses the State-wise and month-wise requirement of fertilizers.
  2. On the basis of requirement projected by DA&FW, the Department of Fertilizers allocates adequate quantities of fertilizers to States by issuing monthly supply plan and continuously monitors the availability.
  3. The movement of all major subsidised fertilizers is monitored throughout the country by an online web-based monitoring system called the Integrated Fertilizer Monitoring System.
  4. Regular weekly video conference is conducted jointly by DA&FW and the Department of Fertilizers with State Agriculture Department officials, and corrective actions are taken to despatch fertilizers as indicated by the State Governments.
  5. The distribution of fertilizers within the State is done by the respective State Government.
  6. Urea is provided to the farmers at a statutorily notified Maximum Retail Price (MRP). The MRP of 45kg bag of urea is ₹242 per bag (exclusive of charges towards neem coating and taxes as applicable). The difference between the delivered cost of urea at farm gate and net market realization by the urea units is given as subsidy to the urea manufacturer/importer by the Government of India. Accordingly, all farmers are being supplied urea at the subsidized rates.

 As per information provided by the Department of Chemicals and Petrochemicals, various initiatives are being taken to support the sector. The details are as under:  

  1. Petroleum, Chemicals and Petrochemicals Investment Regions (PCPIR): To attract investments in chemicals and petrochemicals sector, Department had notified the Petroleum, Chemicals and Petrochemical Investment Region (PCPIR) Policy. PCPIRs are conceptualized as cluster-based model of development with common infrastructure and support services. Three PCPIRs have been set up at Dahej (Gujarat), Vishakhapatnam-Kakinada (Andhra Pradesh) and Paradeep (Odisha). Currently, 2,246 chemical units are functional in these PCIPRs having a cumulative investment of ₹3,49,192 crore and these regions have generated employment of 3.7 lakh persons.
  2. Plastic Parks: The Department implements the Scheme for Setting up of Plastic Parks under the scheme of New Scheme of Petrochemicals. The Scheme promotes setting up of need-based Plastic Parks with requisite state-of-the-art infrastructure and enabling common facilities. The objective is to consolidate and synergize the capacities of downstream plastic processing industry to help increase investment, production and export in the sector as well as generate employment. Under the scheme, the Government of India provides grant funding up to 50% of the project cost to the State Government subject to a ceiling of ₹40 crore per project. In accordance with the Scheme Guidelines, 9 Plastic Parks have been approved so far and the same are at different levels of implementation.

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

There is no provision for Bulk Drug Parks under the Production Linked Incentive (PLI) schemes implemented by the Department of Pharmaceuticals. However, the Department of Pharmaceuticals is implementing another scheme, namely the scheme for Promotion of Bulk Drug Parks, with a budgetary outlay of ₹3,000 crore, under which three bulk drug parks have been approved and are at various stages of development in the States of Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective State implementing agencies. The total project cost of these parks is over ₹6,306.68 crore, with Central assistance to the tune of ₹1,000 crore each for creation of common infrastructure facilities. These parks envisage land and utilities such as power, water, effluent treatment plant, steam, solid waste management and warehouse facilities at a subsidised rate to bulk drug or API manufacturers for units set up in the park. The State implementing agencies of the States concerned have also offered fiscal incentives in the form of capital subsidy on fixed capital investment, interest subsidy, State Goods and Services Tax reimbursement, exemption of stamp duty and registration charges, etc. Further, the scheme provides for applicants for allotment of land in the parks to set up units for manufacturing products prioritised in the PLI Scheme for Bulk Drugs to have priority in land allotment.

While no Bulk Drug Park has been approved for Tamil Nadu under the said scheme, the Government is promoting infrastructure development and investment in the pharmaceutical sector across the country, including Tamil Nadu, through other initiatives such as Scheme for Promotion of Medical Devices Parks and Production Linked Incentive (PLI) Scheme. The details of these schemes are as under:

(i)    Scheme for Promotion of Medical Devices Parks: The Scheme for Promotion of Medical Devices Parks aims to provide easy access to world-class, common infrastructure facilities to medical device units set up in medical device parks. Under this scheme, three parks are being set up and are at an advanced stage of development in Greater Noida, Uttar Pradesh, Ujjain, Madhya Pradesh and Kanchipuram, Tamil Nadu. The total project cost of these Parks is ₹871.11 crore, with Central grant-in-aid to the tune of ₹100 crore each for creation of common infrastructure facilities, which is expected to enhance industry’s competitiveness and reduce production costs through optimisation of resources and economies of scale. Civil construction for the three parks is at the final stages. As of December 2025, 199 medical devices manufacturers have been allotted land in the three parks in a 306.64 acre area and 34 units have commenced construction of their plants.

(ii)   Production Linked Incentive (PLI) Scheme:

1.           PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs in India (commonly known as the PLI Scheme for Bulk Drugs): The scheme, which has a total budgetary outlay of ₹6,940 crore, aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source. The scheme provides financial incentives on the sale of 41 identified KSMs/ DIs/ APIs products manufactured through greenfield projects set up under the scheme. Under the scheme, 48 projects are approved for manufacturing of 33 bulk drugs, out of which 2 projects are approved from the State of Tamil Nadu.

2.           PLI Scheme for Pharmaceuticals: The scheme, which has a total budgetary outlay of ₹15,000 crore, aims to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. It incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. as well as production of KSMs/ DIs/ APIs other than those notified under the PLI Scheme for Bulk Drugs, thereby contributing to self-reliance. Under the scheme, 55 applicants are approved for manufacturing of pharmaceuticals and in-vitro medical devices (IVDs) manufactured through both greenfield and brownfield projects. 16 manufacturing units are situated in the State of Tamil Nadu.

3.           Production Linked Incentive (PLI) scheme for promoting domestic manufacturing of Medical Devices: The scheme has a budgetary outlay of ₹3,420 crore and a five-year performance-linked incentive period from FY2022-23 to FY2026-27. Under the scheme, selected companies are eligible for financial incentive for incremental sales of domestically manufactured medical devices in the radiotherapy, imaging device, anaesthesia, cardio-respiratory and critical care and implant device segments, for a period of five years. Under the scheme, out of total 28 approved projects two have been approved in Tamil Nadu.

 The Department of Pharmaceuticals is implementing the scheme for Promotion of Research   and Innovation in Pharma-MedTech Sector (PRIP) with an approved outlay of ₹ 5000 crore and scheme duration of up to the financial year 2029-30 to strengthen research and innovation by supporting projects across the innovation lifecycle from early research to product development and commercialisation.   Under the scheme, seven Centres of Excellence (CoEs) has been established, one at each National Institute for Pharmaceutical Education and Research, with a focus on strengthening research infrastructure, accelerating innovation, and enhancing industry-academia collaboration in identified areas.  Of these, the CoE at NIPER Hyderabad is focused on Bulk Drugs.

The scheme also provides financial assistance to industries, MSMEs, start-ups for eligible R&D projects for the development or expeditious validation of new medicines; complex generics and biosimilars; and novel medical devices in identified priority areas taken up either in-house or in collaboration with the academia.  The Scheme would incentivize eligible R&D and innovation projects and promote such activities across States including the state of Tamil Nadu.

 At present, there is no such proposal of the Government of India to establish a Bulk Drug Park in the State of Tamil Nadu under the Scheme for Promotion of Bulk Drug Parks.

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

As informed by National Medical Commission (NMC), there is an increase of 48,563 MBBS seats and 29,080 PG seats in the country from Academic Year 2020-21 to 2025-26. The details of the increase in MBBS and PG seats are at Annexure. Furthermore, the Government has approved the addition of 10,023 medical seats under Centrally Sponsored Schemes across government colleges from financial year 2025-26 to 2028-29.

The expansion of medical seats reduces the gap in the healthcare workforce, particularly in underserved region and has a direct bearing on the doctor-population ratio across States. The growing number of medical seats, coupled with improvements in infrastructure and faculty, has made domestic institutions more accessible to Indian students.

NMC, as an apex regulatory body entrusted with the responsibility of maintaining the quality of medical education has notified various Regulations namely Minimum Standards Requirement (MSR), Graduate Medical Education Regulations (GMER), 2023, Maintenance of Standards of Medical Education Regulations, 2023 (MSMER-2023) and Competency-Based Medical Education (CBME) Curriculum Guidelines 2024 to ensure the adherence to prescribed standards in medical education. These regulations are designed to uphold the integrity and quality of medical education and training across the country.

The Union Minister of State for Health and Family Welfare, Smt. Anupriya Patel stated this in a written reply in the Lok Sabha today.

Annexure

Number of MBBS seats from academic year 2020-21 to 2025-26

Sr. No.Academic YearIncrease in MBBS seats
12020-212963
22021-228790
32022-237398
42023-249652
52024-258641
62025-2611119

Number of PG seats from academic year 2020-21 to 2025-26     

Sr. No.Academic YearIncrease in PG seats
12020-214983
22021-224705
32022-232874
42023-244713
52024-254186
62025-267619

The Janaushadhi product basket consists of 2,110 medicines and 315 medical devices and consumables and it covers major therapeutic groups including cardiovascular disease, oncology, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines.

The details of sales made by the Kendras located in Konaseema district is as per Annexure II.

While the demographic data sought are not maintained, currently about 15 lakh customers across the country purchase Janaushadhi products daily from JAKs.

Number of steps have been taken to ensure effective and regular supply of medicines including critical and life saving medicines at Jan Aushadhi Kendras (JAKs), including the following:

  1. Since September 2024, stocking by JAKs of 200 commonly used medicines, consisting of the 100 top-selling medicines in the scheme product basket and 100 fast-selling medicines in the market, has been incentivised, under which JAK owners are eligible for monthly incentive based on the stocks that they maintain of these medicines.
  2. An end-to-end information-technology-enabled supply chain system is in place to connect a robust supply chain system consisting of 5 warehouses and a growing network of distributors across the country.
  3. In addition, with a view to ensure availability of commonly used products, 400 fast-moving products are monitored regularly by the scheme implementing agency {Pharmaceuticals and Medical Devices Bureau of India (PMBI)} and demand for the same is forecasted on an ongoing basis. Further, steps have been taken to digitise the forecasting method to augment the procurement process.

The District-wise number of JAKs opened in the State of Andhra Pradesh as on 31.12.2025

S. No.DistrictNumber of JAKs opened
 Alluri Sitharama Raju2
 Anakapalli7
 Ananthapuramu12
 Annamayya7
 Bapatla8
 Chittoor12
 Dr. B.R. Ambedkar Konaseema8
 East Godavari14
 Eluru11
 Guntur22
 Kakinada5
 Krishna9
 Kurnool20
 Nandyal7
 Ntr16
 Palnadu11
 Parvathipuram Manyam3
 Prakasam16
 Sri Potti Sriramulu Nellore6
 Sri Sathya Sai10
 Srikakulam9
 Tirupati15
 Visakhapatnam10
 Vizianagaram9
 West Godavari14
 Y.S.R.9
Total272

Sales at MRP by JAKs opened in Konaseema District:

S. No.FYSales (Rs. In Cr.)
12022-230.04
22023-240.1
32024-250.14
42025-26 (till 31.12.2025)0.07

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

Under Pradhan Mantri Bhartiya Janaushadhi Pariyojana, a total of 17,990 JAKs have been opened across the country as on 31.12.2025. The State-wise /Union Territory-wise number of JAKs opened across the country is at Annexure I. Under the Scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at rates that are about 50% to 80% cheaper than those of equivalent branded alternatives.

Paragraph 1.5 of the Code of Medical Ethics in the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 requires that every physician should prescribe drugs with generic names legibly and preferably in capital letters and that the physician shall ensure that there is a rational prescription and use of drugs. Moreover, the Medical Council of India has issued circular date 21.04.2017 (Annexure II) directing all registered medical practitioners to comply with the said requirement.

In addition to above, the scheme implementing agency i.e. Pharmaceuticals & Medical Devices Bureau of India (PMBI) takes steps to apprise doctors about the scheme and the benefits of generic medicines. The doctors are briefed about the quality and affordability of Janaushadhi medicines through these campaigns. Further, extensive media campaigns are carried out to create awareness among the citizens so that they can request for prescriptions of generic medicines during consultations with their physicians/doctors.

The State-wise /Union Territory-wise number of JAKs opened as on 31.12.2025

S. No.State / Union territoryNumber of JAKs opened
1Andaman and Nicobar Islands6
2Andhra Pradesh272
3Arunachal Pradesh35
4Assam176
5Bihar1058
6Chandigarh19
7Chhattisgarh345
8Delhi589
9Goa18
10Gujarat848
11Haryana474
12Himachal Pradesh74
13Jammu and Kashmir351
14Jharkhand166
15Karnataka1585
16Kerala1714
17Ladakh3
18Lakshadweep1
19Madhya Pradesh614
20Maharashtra713
21Manipur68
22Meghalaya25
23Mizoram16
24Nagaland22
25Odisha803
26Puducherry33
27Punjab532
28Rajasthan632
29Sikkim15
30Tamil Nadu1515
31Telangana212
32The Dadra and Nagar Haveli and Daman and Diu40
33Tripura33
34Uttar Pradesh3805
35Uttarakhand319
36West Bengal859
 Total17,990

Annexure II

Medical Council of India circular date 21.04.2017

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) scheme, 11 JAKs have been opened in Jamui Parliamentary Constituency of Bihar. Out of 11 JAKs, 1 Kendra has been opened during F.Y. 2025-26. During the F.Y. 2025-26, the JAKs located in the said constituency have reported a sales turnover of ₹ 1.86 Crore till 31.12.2025.

Out of the 11 JAKs operational in Jamui Constituency, no request has been received for One Time Special Incentive from any SC/ST entrepreneur till 31.12.2025. 

Number of steps have been taken to ensure effective and regular supply of medicines including essential diabetes and BP medicines at Jan Aushadhi Kendras (JAKs), including the following:

  1. Since September 2024, stocking by JAKs of 200 commonly used medicines, consisting of the 100 top-selling medicines in the scheme product basket and 100 fast-selling medicines in the market, has been incentivised, under which JAK owners are eligible for monthly incentive based on the stocks that they maintain of these medicines.
  2. An end-to-end information-technology-enabled supply chain system is in place to connect a robust supply chain system consisting of 5 warehouses and a growing network of distributors across the country.
  3.  In addition, with a view to ensure availability of commonly used products, 400 fast-moving products are monitored regularly by the scheme implementing agency {Pharmaceuticals and Medical Devices Bureau of India (PMBI)} and demand for the same is forecasted on an ongoing basis. Further, steps have been taken to digitise the forecasting method to augment the procurement process.

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

Coronary stents [Bare Metal Stents (BMS) and Drug Eluting Stents (DES)] are included in Schedule-I of the Drugs (Prices Control) Order, 2013 (DPCO, 2013) and accordingly NPPA fixes their ceiling prices as per the provisions of DPCO, 2013. The present applicable ceiling price for BMS is ₹10,692.69 and for DES ₹38,933.14. The prices fixed under DPCO, 2013 are applicable across the country. All manufacturers, marketers and importers of stents are required to sell their products within such ceiling price (plus applicable Goods and Service Tax).  Also, NPPA issued a notification dated 12.2.2018, requiring that institutions such as hospitals, nursing homes and clinics performing angioplasty procedures using coronary stents who bill patients directly shall comply with the ceiling prices notified in the notification. Further, the said notification also requires such institutions to specifically and separately mention in their estimate / proforma invoice / final billing, etc. the cost of the coronary stents, its category like bare-metal stent (BMS) or drug-eluting stent (DES), brand name, name of the manufacturer / importer / batch number / specifications and other details.

 Further, as per constitutional provisions, ‘Health’ is a State subject. It is the responsibility of respective State Government / Union Territory Administration to take cognizance of cases of excessive amounts being charged by private hospitals and take action to prevent and control such practices. However, the Government of India, enacted ‘The Clinical Establishments (Registration and Regulation) Act, 2010’ (CE Act) and notified ‘The Clinical Establishments (Central Government) Rules, 2012’ thereunder to provide for registration and regulation of Government as well as private clinical establishments belonging to recognized systems of medicine i.e. Allopathy, Yoga, Naturopathy, Ayurveda, Homoeopathy, Siddha and Unani System of medicines, or any other system of medicine as may be recognised by the Central Government (except those of Armed Forces). The State Governments and Union Territories Administration which have adopted the CE Act are primarily responsible for regulating their hospitals including private hospitals as per provisions of the CE Act and Rules thereunder to ensure the provision of affordable and quality healthcare to patients. As per the CE Act, all the clinical establishments (Government & private) are required to fulfil the conditions of minimum standards of facilities and services and inter-alia, display of rates charged by them at a conspicuous place. The CE Act has empowered a registering authority at the District level under the chairmanship of the District Collector / District Magistrate to take actions including imposing penalties in respect of violation of its provisions.

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

As per the information provided by Department of Health & Family Welfare, total 40 Pharmaceutical manufacturing units are currently operational in Daman.

As per the information provided by Ministry of Enviroment, Forest & Climate Change (MoEFCC), all the operational units are having valid authorization for the handling of Hazardous and Bio-medical waste. There is no Common Effluent Treatment Plant (CETP) in Daman and all the pharmaceuticals manufacturing units are operational under Zero Liquid Discharge system. Further, no cases have been registered against any company for violations under the Environment (Protection) Act, 1986.

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

The Production Linked Incentive (PLI) Scheme for Promoting Domestic Manufacturing of Medical Devices aims to promote domestic manufacturing of medical devices by attracting large investments for creation of domestic manufacturing capacity and incentivising domestic production. The list of high-end medical devices that are currently being manufactured in the country under the scheme is at Annexure.

The setting up of a Medical Device Park each in the States of Uttar Pradesh, Madhya Pradesh and Tamil Nadu, under the Scheme for Promotion of Medical Device Parks, is aimed at developing a highly competitive domestic manufacturing ecosystem by creating a state-of-the-art manufacturing ecosystem that offers plug-and-play facilities to greenfield units set up in these parks. Medical Device Parks offer land at substantially subsidised rates, often coupled with exemptions or concessions on stamp duty, which significantly reduces initial capital outlay on land acquisition and project establishment. This upfront cost relief is particularly important for greenfield investors, as it allows a larger share of their capital to be directed towards plant and machinery, technology acquisition, automation and quality systems, rather than land costs and costs of establishing facilities that are being made available as common facilities in these Parks, such as 3D design and printing, electronic assembly, electromagnetic interference and compatibility centre, moulding, sterilisation, biocompatibility testing, toxicology, electronic parts testing, component testing, gamma radiation facility. By providing such facilities on shared basis, the parks eliminate the need for individual companies to invest in expensive, capital-intensive infrastructure that is often under-utilised if set up in-house. This significantly reduces the per-unit cost of manufacturing, testing and validation, while also shortening product development timelines.

The Capacity Building and Skill Development in Medical Device Sector sub-scheme of the Strengthening of Medical Device Industry scheme is currently in the implementation phase. Under this sub-scheme, specialised high-tech manpower is being developed through post-graduate, PG-diploma and skilling programmes in medical devices. Academic institutions under this sub scheme deliver industry-aligned curriculum with hands-on training in medical device design, production, testing and diagnostics, supported by industry exposure, internships and applied research.

So far, 18 projects have been approved, covering over 12 premier institutions, including IITs, NITs, NIPERs, NIMHANS etc. serving to create about 750 high-tech professionals over the next three years.

The Promotion of Research in Pharma-Medtech Sector (PRIP) scheme has been launched by Department of Pharmaceuticals to provide financial assistance for research and development projects of industry, MSMEs and startups in priority areas, including novel medical devices. With a view to help build specific research capacities in medical devices, tapping industry-academia linkage, institutional strengthening of research infrastructure and nurturing of talent pool has been undertaken through the setting up of a Centre of Excellence on medical devices with advanced facilities at the National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad.

Further, the NIPER Council has set up a NIPER Academia-Industry Coordination Committee as an institutional mechanism to promote strategic coordination between NIPERs and pharmaceuticals and medical devices industry by, among other things, facilitating greater synergies between NIPERs and industry and supporting research-driven growth, innovation, skilling and translation of academic research into industrial applications.

High-end medical devices being manufactured in India under the PLI Scheme

1.Rotational Cobalt Machine

2.Linear Accelerator (LINAC)

3.Laser Ablation System

4.CT Scan

5.MRI

6.MRI Coils

7.Mammography

8.X-ray equipment

9.X- Ray including Fixed Line Frequency (LF) and High Frequency (HF) X-Ray Product

10.C-arm/ Surgical X-Ray C-Arm

11.Cath-Lab

12.PET Detector

13.Digital X-Ray Flat Pannel Detector

14.X - Ray Panels

15.Anesthesia Workstation

16.Anesthesia Unit Ventilators

17.Dialyzer

18.Dialysis Machine

19.Haemodialysis Catheter

20.Peritoneal Dialysis Kits

21.Oxygen Concentrators

22.High Flow Oxygen Devices

23.Intensive Care Ventilators

24.Emergency Ventilators

25.ECG

26.Patient Monitoring System / Patient Monitors

27.Multi-Parameter Monitor

28.Defibrillators / Automated External Defibrillators (AED

29.Bi-Phasic Defibrillators

30.Stress Test System

31.Hip Implants

32.Knee implants

33.Trauma Implants

34.PTCA Balloon Dilation Catheter / PTCA Balloon Catheter/Drug Eluting Balloons

35.Heart Valves

36.Stents/Drug Eluting Stents

37.Intravascular Lithotripsy Catheter System

38.Endocutter

This information was given by Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

©2025 Life Science World. All rights reserved
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram